Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Witzig

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Cancer Biotherapy & Radiopharmaceuticals|September 30, 2004
Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopeniaRussell Schilder, Arturo Molina, Nancy Bartlett, et al.
Blood|March 16, 2004
Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 studyLeo I Gordon, Arturo Molina, Thomas Witzig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2011
Species D adenoviruses as oncolytics against B-cell cancersChristopher Y Chen, Julien S Senac, Eric A Weaver, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 7, 2003
Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trialsGregory A Wiseman, Ellen Kornmehl, Bryan Leigh, et al.
Oncotarget|April 4, 2015
Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphomaChristos Demosthenous, Jing Jing Han, Mary J Stenson, et al.
Blood Advances|April 4, 2019
Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myelomaIlyas Sahin, Yawara Kawano, Romanos Sklavenitis-Pistofidis, et al.
Clinical Lymphoma|September 30, 2004
Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphomaLeo I Gordon, Thomas Witzig, Arturo Molina, et al.
Journal for Immunotherapy of Cancer|June 24, 2022
Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogressionN Nora Bennani, Hyo Jin Kim, Levi D Pederson, et al.
Clinical Genitourinary Cancer|August 6, 2018
Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning?Niraj Shenoy, Mythri Mudireddy, Rangit Vallapureddy, et al.
British Journal of Haematology|April 30, 2015
Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trialAndre Goy, Sevgi Kalayoglu Besisik, Johannes Drach, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Cancer Biotherapy & Radiopharmaceuticals|September 30, 2004
Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopeniaRussell Schilder, Arturo Molina, Nancy Bartlett, et al.
Blood|March 16, 2004
Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 studyLeo I Gordon, Arturo Molina, Thomas Witzig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2011
Species D adenoviruses as oncolytics against B-cell cancersChristopher Y Chen, Julien S Senac, Eric A Weaver, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 7, 2003
Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trialsGregory A Wiseman, Ellen Kornmehl, Bryan Leigh, et al.
Oncotarget|April 4, 2015
Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphomaChristos Demosthenous, Jing Jing Han, Mary J Stenson, et al.
Blood Advances|April 4, 2019
Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myelomaIlyas Sahin, Yawara Kawano, Romanos Sklavenitis-Pistofidis, et al.
Clinical Lymphoma|September 30, 2004
Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphomaLeo I Gordon, Thomas Witzig, Arturo Molina, et al.
Journal for Immunotherapy of Cancer|June 24, 2022
Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogressionN Nora Bennani, Hyo Jin Kim, Levi D Pederson, et al.
Clinical Genitourinary Cancer|August 6, 2018
Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning?Niraj Shenoy, Mythri Mudireddy, Rangit Vallapureddy, et al.
British Journal of Haematology|April 30, 2015
Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trialAndre Goy, Sevgi Kalayoglu Besisik, Johannes Drach, et al.
Pageof 4